Publications by authors named "McBurnie J"
Importance: The need to maintain clinical trial recruitment during the COVID-19 pandemic has precipitated the rapid uptake of digital health for the conduct of clinical trials. Different terms are used in different jurisdictions and clinical contexts, including digital trials, networked trials, teletrials (TT), and decentralized clinical trials (DCT) with a need to agree to terms.
Observations: This clinical care review summarized publications and gray literature, including government policies for the safe conduct of clinical trials using digital health.
Objective: To describe the effectiveness of the public health response to COVID-19 in our local region by documenting detection of SARS-CoV-2 infection by nucleic acid testing (NAT) positivity and seroprevalence.
Methods: In this prospective study (ACTRN12620000487910), symptomatic adult international travellers returning to regional Australia in March 2020 underwent SARS-CoV-2 NAT and SARS-CoV-2-specific serology.
Results: Ninety-nine eligible participants were included.
Article Synopsis
- Regional cancer patients face challenges accessing specialized care, but teletrials provide a solution by allowing participation in clinical trials closer to home.
- A mixed methods study collected quality of life data and conducted interviews to assess the experiences of patients and their carers in both teletrials and traditional metropolitan trial participation.
- Findings indicate that teletrials are viewed positively, offering convenience and reducing participation burden, while highlighting the need for equitable access to cancer trials for all patients, regardless of their location.
Background: Tremelimumab, a fully human cytotoxic T-lymphocyte antigen 4 monoclonal antibody, and PF-3512676, a Toll-like receptor-9 agonist, are targeted immune modulators that elicit durable single-agent antitumour activity in advanced cancer.
Methods: To determine the maximum tolerated dose (MTD) of these agents combined during this phase I study, patients received intravenous tremelimumab (6.0, 10.